



## **NEWS RELEASE**

**Media contact:**

Lee Tokuhara  
Bennet Group  
Phone: 808-531-6087, ext. 105  
Cell: 808-295-7329  
Email: [lee@bennetgroup.com](mailto:lee@bennetgroup.com)

For Immediate Release  
February 10, 2009

### **Tissue Genesis Awarded \$3.62 Million Military Contract**

*Company to Research Treatment Option for PVD*

HONOLULU, HAWAI'I—Tissue Genesis, Inc., an innovator of advanced tissue engineering and cell therapy solutions, announced today that the U.S. Department of Defense has awarded a \$3.62 million contract to the Honolulu-based company. Under the contract, Tissue Genesis will continue its research and development activities focused on additional treatment options for those suffering from Peripheral Vascular Disease (PVD). PVD is a circulation disorder affecting blood vessels outside of the heart, including vessels supplying the hands, feet and legs, which can cause severe pain.

Tissue Genesis will explore transplanting Adipose (fat) derived Stromal Cells (ASCs), isolated from a patient's own fat using the Tissue Genesis Cell Isolation System, directly into tissues damaged by a low blood supply, which is expected to increase circulation and relieve symptoms of PVD. An improvement in circulation is directed at preventing disease progression, which left untreated ultimately results in 130,000 amputations annually.

“The technology developed through this study can provide a more effective and safer form of treatment for patients who suffer from PVD, as well as give military and civilian physicians the ability to use the potentially restorative benefits of the patient's own cells,”

said Anton C. Krucky, President and Chief Executive Officer of Tissue Genesis. “This is a major step to bringing this technology to the forefront, and we greatly appreciate the Department’s recognition of our capabilities to do this advanced research. This is our sixth contract, with a total of nearly \$24 million awarded to us,” Krucky added.

Tissue Genesis has dedicated a significant amount of time towards researching and developing adipose derived regenerative medical therapies. Through the results acquired from the Department of Defense contract, Tissue Genesis plans to eventually use privately raised funds to pursue the Food and Drug Administration regulatory process.

PVD affects between eight and 20 million people in the United States. By 2020, the number is expected to increase by 43 percent. Approximately 25 percent of patients with PVD and intermittent claudication, which is usually associated with inadequate blood supply to the muscles causing pain and weakness in the legs that disappears after rest, will progress to Critical Limb Ischemia (CLI). Current therapies for PVD and CLI range from surgical bypass to over-the-counter analgesics. Surgical remedies rarely relieve all symptoms, and for some patients with CLI, the only option for relief from the pain or gangrene is amputation.

**About Tissue Genesis, Inc.**

Tissue Genesis, Inc. ([www.tissuegenesis.com](http://www.tissuegenesis.com)) is a leader in adipose (fat) derived regenerative medicine solutions addressing a wide range of therapeutic needs including vascular, cardiovascular, and other regenerative medical applications. The company expects its technology, expertise and products to isolate autologous, adipose derived regenerative cells at the point of care for immediate patient needs. Through its business partners, such as Bioheart, SpineSmith, and Vet-Stem, the company is extending the development and application of its technology and platform products to reach worldwide markets in the potential use of cell therapy.

**Safe Harbor Statement**

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Tissue Genesis, Inc., and members of its management as well as the assumptions on which such statements are based. There can be no assurance that Tissue Genesis will be able to commercially develop its therapeutic cell technology or products, that necessary regulatory approvals will be obtained, that any clinical trials will be successful, or that the proposed treatments will prove to be safe and/or effective. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.